[
    [
        {
            "time": "2021-02-09",
            "original_text": "Eli Lilly's COVID-19 treatment now authorized high-risk patients 'of any age'",
            "features": {
                "keywords": [
                    "Lilly",
                    "COVID-19",
                    "treatment",
                    "authorized",
                    "high-risk",
                    "patients"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly's COVID-19 treatment now authorized high-risk patients 'of any age'",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "UPDATE 1-FDA clears use of Lilly's COVID-19 antibody therapy for kids",
            "features": {
                "keywords": [
                    "FDA",
                    "clears",
                    "Lilly",
                    "COVID-19",
                    "antibody",
                    "therapy",
                    "kids"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "UPDATE 1-FDA clears use of Lilly's COVID-19 antibody therapy for kids",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "Lilly's COVID-19 antibody treatment authorized for young children and infants",
            "features": {
                "keywords": [
                    "Lilly",
                    "COVID-19",
                    "antibody",
                    "treatment",
                    "authorized",
                    "young",
                    "children",
                    "infants"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's COVID-19 antibody treatment authorized for young children and infants",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12",
            "features": {
                "keywords": [
                    "Lilly",
                    "bamlanivimab",
                    "etesevimab",
                    "neutralizing",
                    "antibody",
                    "therapy",
                    "emergency",
                    "use",
                    "COVID-19",
                    "patients",
                    "under",
                    "age",
                    "12"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]